48 results
Page 2 of 3
8-K
EX-10.1
ueosdaf2s
23 Apr 21
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-99.1
ekn36
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
424B5
cphzhet8yuc 5ayldb46
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
ib6jgquo
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
k8lu9lpjnumi45g
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
b2jc9e
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.1
6b1 o0bj0
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.2
p8ha xjd8jd3
23 Nov 20
Consolidated Financial Statements
12:00am
424B3
vnzxke6owuoqrrd
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
a4aorzx1lq5ikm
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
i956fje8qjh73 afgj
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
phyz47
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
fs3sxhtjdjrv02zb
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.2
p5vmt2 wb8qo9lr2kfg
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.4
f4vuqi
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm